"Gone in a puff of smoke" - CannTrust provides patients with a safer alternative to consume medical cannabis

Vapourizing is the preferred consumption method among Canadian physicians

VAUGHAN, ON, Feb. 27, 2015 /CNW/ - Today, CannTrust, Canada's only pharmacist-controlled and operated producer and distributor of medical cannabis announced an incentive offer for qualified patients that encourages vapourizing to consume medical cannabis. 

In a partnership with Arizer, a leading Canadian innovator of personal vapourizers, patients can now access the latest in vapour technology with an exclusive price for three devices, not offered at these prices by any other Health Canada approved provider of medical cannabis.

"Patient safety is our priority and we've built our business on that," says Normal Paul, Chairman of CannTrust.  "We've created a state-of-the-art growing and testing facility to ensure our patients have access to consistent quality medical cannabis in Canada.  It would be irresponsible for us not to make every effort to ensure patients have access to safe consumption and that is what our vapourizer program is all about."

CannTrust patients who place any order of 15 grams or more of medical cannabis can purchase one of three vapourizers for the lowest price in Canada. The patient can choose from three different starter packs depending on which vapourizer model selected.

Combo pack A includes the Solo model for $250, which includes the vapourizer and 15 grams of medical cannabis. (Just a Solo model retails for $224.)  More advanced packages include the Extreme model with 15 grams of medical cannabis for $265 or the Air model for only $295.

"We are pleased to introduce the CannTrust Starter Pack, which provides quality vapourizers and cannabis at a very affordable price," adds Paul.

Vapourizing involves placing raw cannabis into a personal vaping device. The cannabis is then heated until just before the point of combustion, which turns the elements of the plant into a gas that is released as a vapour.  The cannabinoid levels produced by vapourizing herbal cannabis are comparable to that of smoking, and vapourizing does not result in exposure to combustion gasses, including carbon monoxide.

"Inhaling combusted material, be it tobacco or cannabis, is harmful and presents a negative health-impact for patients," says Dr. Danial Schecter, Executive Director of the Cannabinoid Medical Clinic. "Patients who decide to incorporate cannabis into their treatment need to consider alternative delivery methods.  Current evidence suggests that patients who vapourize cannabis instead of smoking do not develop symptoms of chronic bronchitis, including shortness of breath and chronic cough."

The team at CannTrust supports widespread guidance from the medical community who prefer that patients consume medical cannabis through vapour. Research has been conducted to compare the safety and efficacy of vapourizing versus smoking and the consensus is clear – vapourizing medial cannabis presents a number of advantages for patients, such as a faster absorption time, increased potency and no reported adverse health events compared to those who smoke. 

For more information on the new vapourizer program, please visit canntrust.ca/shop/

About Arizer, Inc.

Arizer is based in Canada and has been researching, designing and manufacturing quality products, such as the Arizer Solo, Extreme Q and V-Tower for nearly a decade.

About CannTrust Inc.

CannTrust Inc. is Canada's only pharmacist-controlled and operated producer and distributor of medical cannabis. Federally licensed and regulated, CannTrust brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry.

Based in Vaughan, Ontario, CannTrust's 40,000 square foot state-of-the-art hydroponic facility employs strict quality control procedures allowing for the continuous production and harvest of pharmaceutical-grade medical cannabis for patients in need.

CannTrust is committed to research and innovation and to contributing to the growing body of evidence-based research for the use and efficacy of medical cannabis.

The company supports ongoing patient education about medical cannabis across Canada through partnerships with a variety of patient and physician-based organizations, and provides a patient assistance program to support patients with financial needs.

For more information, visit canntrust.ca or call 1-855-RX4-CANN (794-2266).

SOURCE CannTrust Inc.

Tova Manett, CannTrust Inc., [email protected], 647-872-2305